Increased HRD score in cisplatin resistant penile cancer cells

Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availabilit...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 22; no. 1; pp. 1352 - 14
Main Authors:	Winkelmann, Ria, Bankov, Katrin, Döring, Claudia, Cinatl, Jaroslav, Grothe, Sebastian, Rothweiler, Florian, Michaelis, Martin, Schmitt, Christina, Wild, Peter J., Demes, Melanie, Cinatl, Jindrich, Vallo, Stefan
Format:	Journal Article
Language:	English
Published:	London BioMed Central 23.12.2022 BioMed Central Ltd BMC
Subjects:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Biomedical and Life Sciences Biomedicine Cancer Research Care and treatment Cell Line, Tumor Cell lines Chemoresistance Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Development and progression Diagnosis Dosage and administration Drug resistance Drug Resistance, Neoplasm - genetics Fluorouracil - pharmacology Fluorouracil - therapeutic use Health Promotion and Disease Prevention Homologous recombination deficiency Humans Male Medicine/Public Health Oncology Patient outcomes Penile cancer Penile carcinomas Penile Neoplasms - drug therapy Risk factors Surgical Oncology Germany Penile carcinomas Homologous recombination deficiency Cell lines Chemoresistance
ISSN:	1471-2407, 1471-2407
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. Methods We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1 r CDDP 2500 , adapted to 2500 ng/ml CDDP; UKF-PEC-1 r 5-FU 500 , adapted to 500 ng/ml 5- FU; UKF-PEC1 r CDDP 2500 / r 5-FU 500 , adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1 r CDDP 2500 , UKF-PEC-1 r 5-FU 500 , UKF-PEC1 r CDDP 2500 / r 5-FU 500 , and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. Results and conclusions The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1 r CDDP 2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1 r CDDP 2500 did not display sensitivity to PARP inhibitors.
AbstractList	Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. Methods We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1.sup.rCDDP.sup.2500, adapted to 2500 ng/ml CDDP; UKF-PEC-1.sup.r5-FU.sup.500, adapted to 500 ng/ml 5- FU; UKF-PEC1.sup.rCDDP.sup.2500/.sup.r5-FU.sup.500, adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1.sup.rCDDP.sup.2500, UKF-PEC-1.sup.r5-FU.sup.500, UKF-PEC1.sup.rCDDP.sup.2500/.sup.r5-FU.sup.500, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. Results and conclusions The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1.sup.rCDDP.sup.2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1.sup.rCDDP.sup.2500 did not display sensitivity to PARP inhibitors. Keywords: Penile carcinomas, Cell lines, Chemoresistance, Homologous recombination deficiency Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1.sup.rCDDP.sup.2500, adapted to 2500 ng/ml CDDP; UKF-PEC-1.sup.r5-FU.sup.500, adapted to 500 ng/ml 5- FU; UKF-PEC1.sup.rCDDP.sup.2500/.sup.r5-FU.sup.500, adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1.sup.rCDDP.sup.2500, UKF-PEC-1.sup.r5-FU.sup.500, UKF-PEC1.sup.rCDDP.sup.2500/.sup.r5-FU.sup.500, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1.sup.rCDDP.sup.2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1.sup.rCDDP.sup.2500 did not display sensitivity to PARP inhibitors. Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy.BACKGROUND/INTRODUCTIONPenile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy.We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1rCDDP2500, adapted to 2500 ng/ml CDDP; UKF-PEC-1r5-FU500, adapted to 500 ng/ml 5- FU; UKF-PEC1rCDDP2500/r5-FU500, adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1rCDDP2500, UKF-PEC-1r5-FU500, UKF-PEC1rCDDP2500/r5-FU500, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib.METHODSWe generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1rCDDP2500, adapted to 2500 ng/ml CDDP; UKF-PEC-1r5-FU500, adapted to 500 ng/ml 5- FU; UKF-PEC1rCDDP2500/r5-FU500, adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1rCDDP2500, UKF-PEC-1r5-FU500, UKF-PEC1rCDDP2500/r5-FU500, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib.The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1rCDDP2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1rCDDP2500 did not display sensitivity to PARP inhibitors.RESULTS AND CONCLUSIONSThe chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1rCDDP2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1rCDDP2500 did not display sensitivity to PARP inhibitors. Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. Methods We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1 r CDDP 2500 , adapted to 2500 ng/ml CDDP; UKF-PEC-1 r 5-FU 500 , adapted to 500 ng/ml 5- FU; UKF-PEC1 r CDDP 2500 / r 5-FU 500 , adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1 r CDDP 2500 , UKF-PEC-1 r 5-FU 500 , UKF-PEC1 r CDDP 2500 / r 5-FU 500 , and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. Results and conclusions The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1 r CDDP 2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1 r CDDP 2500 did not display sensitivity to PARP inhibitors. Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1 CDDP , adapted to 2500 ng/ml CDDP; UKF-PEC-1 5-FU , adapted to 500 ng/ml 5- FU; UKF-PEC1 CDDP / 5-FU , adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1 CDDP , UKF-PEC-1 5-FU , UKF-PEC1 CDDP / 5-FU , and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1 CDDP was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1 CDDP did not display sensitivity to PARP inhibitors. Abstract Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance against standard therapy could help to understand molecular mechanisms underlying chemotherapy resistance and to identify candidate treatments for an efficient second line therapy. Methods We generated a cell line from a humanpapilloma virus (HPV) negative penile squamous cell carcinoma (UKF-PEC-1). This cell line was subject to chronic exposure to chemotherapy with CDDP and / or 5-FU to induce acquired resistance in the newly established chemo-resistant sublines (PEC-1rCDDP2500, adapted to 2500 ng/ml CDDP; UKF-PEC-1r5-FU500, adapted to 500 ng/ml 5- FU; UKF-PEC1rCDDP2500/r5-FU500, adapted to 2500 ng/ml CDDP and 500 ng/ml 5 -FU). Afterwards cell line pellets were formalin-fixed, paraffin embedded and subject to sequencing as well as testing for homologous recombination deficiency (HRD). Additionally, exemplary immunohistochemical stainings for p53 and gammaH2AX were applied for verification purposes. Finally, UKF-PEC-1rCDDP2500, UKF-PEC-1r5-FU500, UKF-PEC1rCDDP2500/r5-FU500, and UKF-PEC-3 (an alternative penis cancer cell line) were tested for sensitivity to paclitaxel, docetaxel, olaparib, and rucaparib. Results and conclusions The chemo-resistant sublines differed in their mutational landscapes. UKF-PEC-1rCDDP2500 was characterized by an increased HRD score, which is supposed to be associated with increased PARP inhibitor and immune checkpoint inhibitor sensitivity in cancer. However, UKF-PEC-1rCDDP2500 did not display sensitivity to PARP inhibitors.
ArticleNumber	1352
Audience	Academic
Author	Michaelis, Martin Cinatl, Jindrich Vallo, Stefan Winkelmann, Ria Cinatl, Jaroslav Bankov, Katrin Demes, Melanie Grothe, Sebastian Schmitt, Christina Döring, Claudia Rothweiler, Florian Wild, Peter J.
Author_xml	– sequence: 1 givenname: Ria surname: Winkelmann fullname: Winkelmann, Ria email: ria.winkelmann@kgu.de organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt – sequence: 2 givenname: Katrin surname: Bankov fullname: Bankov, Katrin organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt – sequence: 3 givenname: Claudia surname: Döring fullname: Döring, Claudia organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt – sequence: 4 givenname: Jaroslav surname: Cinatl fullname: Cinatl, Jaroslav organization: Dr. Petra Joh Forschungshaus – sequence: 5 givenname: Sebastian surname: Grothe fullname: Grothe, Sebastian organization: Dr. Petra Joh Forschungshaus, Institute of Medical Virology, University Hospital Frankfurt – sequence: 6 givenname: Florian surname: Rothweiler fullname: Rothweiler, Florian organization: Dr. Petra Joh Forschungshaus, Institute of Medical Virology, University Hospital Frankfurt – sequence: 7 givenname: Martin surname: Michaelis fullname: Michaelis, Martin organization: School of Biosciences, University of Kent – sequence: 8 givenname: Christina surname: Schmitt fullname: Schmitt, Christina organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt – sequence: 9 givenname: Peter J. surname: Wild fullname: Wild, Peter J. organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt Institute for Advanced Studies (FIAS) – sequence: 10 givenname: Melanie surname: Demes fullname: Demes, Melanie organization: Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt – sequence: 11 givenname: Jindrich surname: Cinatl fullname: Cinatl, Jindrich organization: Dr. Petra Joh Forschungshaus, Institute of Medical Virology, University Hospital Frankfurt – sequence: 12 givenname: Stefan surname: Vallo fullname: Vallo, Stefan organization: Institute of Medical Virology, University Hospital Frankfurt, Department of Urology, University Hospital Frankfurt, Urologie an der Zeil
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36564761$$D View this record in MEDLINE/PubMed
BookMark	eNp9kl2L1DAYhYusuB_6B7yQgiB60TVJ2zS9WVjWjx1YEFa9Dm_St50MnWRMUtF_b2a7K1ORJRcJyXMOyck5zY6ss5hlLyk5p1Tw94EyIeqCMFZQUpWsaJ5kJ7RqaMEq0hwdrI-z0xA2hNBGEPEsOy55zauG05PsYmW1RwjY5de3H_Kgncfc2FybsBshppXHYEIEG_MdWjNirsFq9LnGcQzPs6c9jAFf3M9n2fdPH79dXRc3Xz6vri5vCs2rKhbAa9JBy6jCuhXIBNSKQKvainBghCnQQokSGMWqauoeWU1pW4KuuFZKdeVZtpp9OwcbufNmC_63dGDk3YbzgwQfjR5REp1eJpqeMKErwUvgogdFeuxEzToFyeti9tpNaoudRhs9jAvT5Yk1azm4n7JtRMuZSAZv7w28-zFhiHJrwj4OsOimIFlTC0pTxDyhr2d0gHQ1Y3uXHPUel5dNSUktSlIm6vw_VBodbo1On96n3JeCdwtBYiL-igNMIcjV19sl--aAXSOMcR3cOEXjbFiCrw5z-RvIQ1kSIGZAexeCx15qE2Hvk65rRkmJ3PdSzr2UqZfyrpeySVL2j_TB_VFROYtCgu2AXm7c5G3q2WOqP7fZ8Xg
CitedBy_id	crossref_primary_10_1016_j_ucl_2024_03_013 crossref_primary_10_3390_ijms252212142
Cites_doi	10.3390/CANCERS12051080 10.1002/1097-0142 10.2302/KJM.38.277 10.1038/cddis.2011.129 10.3389/FCELL.2020.564601 10.1200/JCO.2022.40.6_SUPPL.004 10.1038/S41419-018-0736-1 10.1038/S41698-022-00276-6 10.3390/CANCERS13102323/S1 10.1016/J.LUNGCAN.2021.07.011 10.1177/1010428317695931/ASSET/IMAGES/LARGE/10.1177_1010428317695931-FIG2.JPEG 10.1620/TJEM.88.9 10.1038/NCOMMS3126 10.3390/CANCERS14051245 10.1038/BJC.2012.356 10.1016/J.SEMCDB.2011.07.019 10.1016/J.CCR.2012.07.016 10.1016/S0022-5347(17)37327-5 10.18632/ONCOTARGET.24688 10.1038/S41392-020-00437-8 10.1186/1471-2407-13-484 10.1007/S00292-021-00950-9/FIGURES/2 10.1016/S0002-9440(10)62506-0 10.1080/10409238.2021.1881433 10.1097/PAS.0B013E3182113402 10.3390/cancers13030460 10.1016/J.JURO.2012.01.035 10.1038/s41598-020-71810-4 10.1002/IJC.32373 10.1093/nar/gkx1153 10.1038/NRC2820 10.1159/000495251 10.1158/1078-0432.CCR-15-2477 10.1200/JCO.2021.39.6_SUPPL.2 10.1007/S00432-021-03514-9 10.3238/ARZTEBL.2018.0646 10.1093/nar/gky1015 10.1111/bju.13071 10.4155/FMC-2020-0240 10.1016/j.eururo.2016.02.029 10.1158/2159-8290.CD-17-0151 10.1038/s41523-018-0066-6 10.3390/IJMS23010251 10.1007/s13577-021-00630-z 10.1002/CYTO.B.20450 10.1186/S43556-020-00023-Y 10.20517/CDR.2019.005 10.3390/CELLS10040814/S1 10.1172/JCI154095 10.1016/J.PRP.2020.152863 10.1016/J.TRANON.2021.101267 10.1038/s41379-020-00731-4 10.1159/000176016 10.1038/CDDIS.2011.129 10.2147/OTT.S275688 10.4251/WJGO.V14.I1.253 10.1016/J.COMPBIOLCHEM.2019.107155 10.3390/CELLS9071678 10.1002/MC.23185 10.1002/IJC.33990 10.1016/J.UROLONC.2017.09.014 10.1007/S13277-016-4951-Z 10.1038/NATURE09727 10.3390/CANCERS12030532 10.1038/sigtrans.2017.63 10.21037/tau.2017.06.27 10.1093/carcin/bgy086 10.1007/S00428-022-03271-1 10.1634/THEONCOLOGIST.2015-0241 10.1158/1078-0432.CCR-13-0259 10.3892/OR_00000692 10.1186/S13046-021-02093-4 10.1158/0008-5472.CAN-06-4261
ContentType	Journal Article
Copyright	The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd.
Copyright_xml	– notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 5PM DOA
DOI	10.1186/s12885-022-10432-7
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1471-2407
EndPage	14
ExternalDocumentID	oai_doaj_org_article_0c47687f028c4863a68fab0fed852dba PMC9789628 A731058303 36564761 10_1186_s12885_022_10432_7
Genre	Journal Article
GeographicLocations	Germany
GeographicLocations_xml	– name: Germany
GrantInformation_xml	– fundername: Johann Wolfgang Goethe-Universität, Frankfurt am Main (1022) – fundername: ;
GroupedDBID	--- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c644t-a650da921be598e28a5b0a9b9406a202bac8b83a21e4475fe251193ac46cbbbd3
IEDL.DBID	RSV
ISICitedReferencesCount	4
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000903531000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1471-2407
IngestDate	Mon Nov 10 04:35:10 EST 2025 Tue Nov 04 02:07:14 EST 2025 Fri Sep 05 09:36:54 EDT 2025 Tue Nov 11 10:19:07 EST 2025 Tue Nov 04 17:57:18 EST 2025 Thu Nov 13 16:45:14 EST 2025 Thu May 22 21:15:00 EDT 2025 Thu Jan 02 22:53:53 EST 2025 Sat Nov 29 06:42:42 EST 2025 Tue Nov 18 19:36:57 EST 2025 Sat Sep 06 07:18:37 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Penile carcinomas Homologous recombination deficiency Cell lines Chemoresistance
Language	English
License	2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c644t-a650da921be598e28a5b0a9b9406a202bac8b83a21e4475fe251193ac46cbbbd3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://link.springer.com/10.1186/s12885-022-10432-7
PMID	36564761
PQID	2758116566
PQPubID	23479
PageCount	14
ParticipantIDs	doaj_primary_oai_doaj_org_article_0c47687f028c4863a68fab0fed852dba pubmedcentral_primary_oai_pubmedcentral_nih_gov_9789628 proquest_miscellaneous_2758116566 gale_infotracmisc_A731058303 gale_infotracacademiconefile_A731058303 gale_incontextgauss_ISR_A731058303 gale_healthsolutions_A731058303 pubmed_primary_36564761 crossref_citationtrail_10_1186_s12885_022_10432_7 crossref_primary_10_1186_s12885_022_10432_7 springer_journals_10_1186_s12885_022_10432_7
PublicationCentury	2000
PublicationDate	2022-12-23
PublicationDateYYYYMMDD	2022-12-23
PublicationDate_xml	– month: 12 year: 2022 text: 2022-12-23 day: 23
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	BMC cancer
PublicationTitleAbbrev	BMC Cancer
PublicationTitleAlternate	BMC Cancer
PublicationYear	2022
Publisher	BioMed Central BioMed Central Ltd BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: BMC
References	JJ Muñoz (10432_CR18) 2016; 37 N Zhang (10432_CR63) 2020; 13 JG Tate (10432_CR26) 2019; 47 FV Shammas (10432_CR9) 1992; 147 R Stoehr (10432_CR52) 2019; 86 J Ryan (10432_CR56) 2012; 107 G Aita (10432_CR22) 2015; 116 10432_CR23 A Thomas (10432_CR24) 2021; 13 M Michaelis (10432_CR49) 2020; 12 N Starita (10432_CR35) 2022; 150 10432_CR65 10432_CR20 10432_CR64 10432_CR27 T Tsukamoto (10432_CR16) 1989; 38 TL Lotan (10432_CR73) 2021; 34 A Gkountakos (10432_CR54) 2018; 39 T Rothenburger (10432_CR48) 2021; 40 B Nazha (10432_CR33) 2022; 40 LZ Liu (10432_CR68) 2007; 67 SJ Young (10432_CR41) 2021; 56 SM Ali (10432_CR34) 2016; 21 10432_CR61 LT Melinda (10432_CR28) 2016; 22 N Pfarr (10432_CR70) 2021; 42 S Clark-Garvey (10432_CR43) 2021; 131 OW Hakenberg (10432_CR1) 2018; 115 J Domingo-Domenech (10432_CR19) 2012; 22 C Protzel (10432_CR7) 2009; 82 IA Bley (10432_CR10) 2022; 15 PE Spiess (10432_CR53) 2021; 39 10432_CR12 10432_CR11 10432_CR55 CG Mullighan (10432_CR62) 2011; 471 I Yamane (10432_CR15) 1966; 88 10432_CR59 10432_CR14 10432_CR58 MA Rubin (10432_CR4) 2001; 159 10432_CR13 10432_CR57 MJ Landrum (10432_CR25) 2018; 46 A Chaux (10432_CR6) 2011; 35 J-I Tanuma (10432_CR39) 2010; 23 CM Naumann (10432_CR17) 2012; 187 Y Wang (10432_CR38) 2019; 145 PL Olive (10432_CR51) 2009; 76B SV Sharma (10432_CR30) 2010; 10 M Michaelis (10432_CR40) 2011; 2 W Zheng (10432_CR42) 2022; 14 C Yang (10432_CR69) 2022; 35 L Golmard (10432_CR67) 2013; 13 VV Palla (10432_CR50) 2017; 39 S Tadesse (10432_CR46) 2021; 13 J Macedo (10432_CR32) 2020; 59 K Attalla (10432_CR2) 2018; 36 10432_CR29 AD Whale (10432_CR60) 2017; 2 M Michaelis (10432_CR21) 2011; 2 10432_CR3 10432_CR5 10432_CR76 10432_CR31 10432_CR75 SE Rebuzzi (10432_CR45) 2022; 14 10432_CR37 10432_CR36 F Wang (10432_CR44) 2021; 160 10432_CR8 10432_CR74 N Suwaki (10432_CR66) 2011; 22 SM Sweeney (10432_CR47) 2017; 7 10432_CR72 10432_CR71
References_xml	– volume: 12 start-page: 1080 year: 2020 ident: 10432_CR49 publication-title: Cancers basel doi: 10.3390/CANCERS12051080 – ident: 10432_CR8 doi: 10.1002/1097-0142 – volume: 38 start-page: 277 year: 1989 ident: 10432_CR16 publication-title: Keio J Med doi: 10.2302/KJM.38.277 – volume: 2 start-page: e243 year: 2011 ident: 10432_CR21 publication-title: Cell Death Dis. doi: 10.1038/cddis.2011.129 – ident: 10432_CR75 doi: 10.3389/FCELL.2020.564601 – ident: 10432_CR14 – volume: 40 start-page: 4 year: 2022 ident: 10432_CR33 publication-title: Am Soc Clin Oncol doi: 10.1200/JCO.2022.40.6_SUPPL.004 – ident: 10432_CR13 doi: 10.1038/S41419-018-0736-1 – ident: 10432_CR74 doi: 10.1038/S41698-022-00276-6 – volume: 13 start-page: 2323 year: 2021 ident: 10432_CR24 publication-title: Cancers (Basel) doi: 10.3390/CANCERS13102323/S1 – volume: 160 start-page: 1 year: 2021 ident: 10432_CR44 publication-title: Lung Cancer doi: 10.1016/J.LUNGCAN.2021.07.011 – volume: 39 start-page: 1 year: 2017 ident: 10432_CR50 publication-title: Tumor Biol doi: 10.1177/1010428317695931/ASSET/IMAGES/LARGE/10.1177_1010428317695931-FIG2.JPEG – volume: 88 start-page: 9 year: 1966 ident: 10432_CR15 publication-title: Tohoku J Exp Med doi: 10.1620/TJEM.88.9 – ident: 10432_CR29 doi: 10.1038/NCOMMS3126 – volume: 14 start-page: 1245 year: 2022 ident: 10432_CR45 publication-title: Cancers Basel). doi: 10.3390/CANCERS14051245 – volume: 107 start-page: 967 year: 2012 ident: 10432_CR56 publication-title: Br J Cancer doi: 10.1038/BJC.2012.356 – volume: 22 start-page: 898 year: 2011 ident: 10432_CR66 publication-title: Semin Cell Dev Biol Elsevier Ltd doi: 10.1016/J.SEMCDB.2011.07.019 – volume: 22 start-page: 373 year: 2012 ident: 10432_CR19 publication-title: Cancer Cell. NIH Public Access doi: 10.1016/J.CCR.2012.07.016 – volume: 147 start-page: 630 year: 1992 ident: 10432_CR9 publication-title: J Urol. J Urol doi: 10.1016/S0022-5347(17)37327-5 – ident: 10432_CR58 doi: 10.18632/ONCOTARGET.24688 – ident: 10432_CR61 doi: 10.1038/S41392-020-00437-8 – volume: 13 start-page: 484 year: 2013 ident: 10432_CR67 publication-title: BMC Cancer doi: 10.1186/1471-2407-13-484 – volume: 42 start-page: 391 year: 2021 ident: 10432_CR70 publication-title: Pathologe doi: 10.1007/S00292-021-00950-9/FIGURES/2 – volume: 159 start-page: 1211 year: 2001 ident: 10432_CR4 publication-title: Am J Pathol Am Soc Invest Pathol doi: 10.1016/S0002-9440(10)62506-0 – volume: 56 start-page: 157 year: 2021 ident: 10432_CR41 publication-title: Crit Rev Biochem Mol Biol. doi: 10.1080/10409238.2021.1881433 – ident: 10432_CR57 – volume: 35 start-page: 553 year: 2011 ident: 10432_CR6 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0B013E3182113402 – ident: 10432_CR12 doi: 10.3390/cancers13030460 – volume: 187 start-page: 2236 year: 2012 ident: 10432_CR17 publication-title: J Urol doi: 10.1016/J.JURO.2012.01.035 – ident: 10432_CR37 doi: 10.1038/s41598-020-71810-4 – volume: 145 start-page: 1280 year: 2019 ident: 10432_CR38 publication-title: Int J Cancer doi: 10.1002/IJC.32373 – volume: 46 start-page: D1062 year: 2018 ident: 10432_CR25 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkx1153 – volume: 10 start-page: 241 year: 2010 ident: 10432_CR30 publication-title: Nat Rev Cancer. doi: 10.1038/NRC2820 – volume: 86 start-page: 145 year: 2019 ident: 10432_CR52 publication-title: Pathobiology doi: 10.1159/000495251 – volume: 22 start-page: 3764 year: 2016 ident: 10432_CR28 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-15-2477 – volume: 39 start-page: 2 year: 2021 ident: 10432_CR53 publication-title: Am Soc Clin Oncol doi: 10.1200/JCO.2021.39.6_SUPPL.2 – ident: 10432_CR55 doi: 10.1007/S00432-021-03514-9 – volume: 115 start-page: 646 year: 2018 ident: 10432_CR1 publication-title: Dtsch Arztebl Int. Deutscher Arzte-Verlag GmbH. doi: 10.3238/ARZTEBL.2018.0646 – volume: 47 start-page: D941 year: 2019 ident: 10432_CR26 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gky1015 – volume: 116 start-page: 584 year: 2015 ident: 10432_CR22 publication-title: BJU Int. doi: 10.1111/bju.13071 – volume: 13 start-page: 117 year: 2021 ident: 10432_CR46 publication-title: Future Med Chem. doi: 10.4155/FMC-2020-0240 – ident: 10432_CR3 doi: 10.1016/j.eururo.2016.02.029 – volume: 7 start-page: 818 year: 2017 ident: 10432_CR47 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0151 – ident: 10432_CR27 doi: 10.1038/s41523-018-0066-6 – ident: 10432_CR36 doi: 10.3390/IJMS23010251 – volume: 35 start-page: 199 year: 2022 ident: 10432_CR69 publication-title: Hum Cell. doi: 10.1007/s13577-021-00630-z – volume: 76B start-page: 79 year: 2009 ident: 10432_CR51 publication-title: Cytom Part B Clin Cytom doi: 10.1002/CYTO.B.20450 – ident: 10432_CR5 – ident: 10432_CR65 doi: 10.1186/S43556-020-00023-Y – ident: 10432_CR23 doi: 10.20517/CDR.2019.005 – ident: 10432_CR11 doi: 10.3390/CELLS10040814/S1 – volume: 131 start-page: e154095 year: 2021 ident: 10432_CR43 publication-title: J Clin Invest. doi: 10.1172/JCI154095 – ident: 10432_CR72 doi: 10.1016/J.PRP.2020.152863 – volume: 15 start-page: 101267 year: 2022 ident: 10432_CR10 publication-title: Transl Oncol. Neoplasia Press doi: 10.1016/J.TRANON.2021.101267 – volume: 34 start-page: 1185 year: 2021 ident: 10432_CR73 publication-title: Mod Pathol doi: 10.1038/s41379-020-00731-4 – volume: 82 start-page: 1 year: 2009 ident: 10432_CR7 publication-title: Urol Int. Urol Int. doi: 10.1159/000176016 – volume: 2 start-page: e243 year: 2011 ident: 10432_CR40 publication-title: Cell Death Dis doi: 10.1038/CDDIS.2011.129 – volume: 13 start-page: 12797 year: 2020 ident: 10432_CR63 publication-title: Onco Targets Ther. doi: 10.2147/OTT.S275688 – volume: 14 start-page: 253 year: 2022 ident: 10432_CR42 publication-title: World J Gastrointest Oncol. doi: 10.4251/WJGO.V14.I1.253 – ident: 10432_CR59 doi: 10.1016/J.COMPBIOLCHEM.2019.107155 – ident: 10432_CR64 doi: 10.3390/CELLS9071678 – volume: 59 start-page: 604 year: 2020 ident: 10432_CR32 publication-title: Mol Carcinog. doi: 10.1002/MC.23185 – volume: 150 start-page: 1879 year: 2022 ident: 10432_CR35 publication-title: Int J cancer. Int J Cancer doi: 10.1002/IJC.33990 – volume: 36 start-page: 17 issue: 14 year: 2018 ident: 10432_CR2 publication-title: Urol Oncol Semin Orig Investig. doi: 10.1016/J.UROLONC.2017.09.014 – volume: 37 start-page: 11375 year: 2016 ident: 10432_CR18 publication-title: Tumour Biol doi: 10.1007/S13277-016-4951-Z – volume: 471 start-page: 235 year: 2011 ident: 10432_CR62 publication-title: Nature doi: 10.1038/NATURE09727 – ident: 10432_CR76 doi: 10.3390/CANCERS12030532 – volume: 2 start-page: 1 year: 2017 ident: 10432_CR60 publication-title: Signal Transduct Target Ther doi: 10.1038/sigtrans.2017.63 – ident: 10432_CR20 doi: 10.21037/tau.2017.06.27 – volume: 39 start-page: 971 year: 2018 ident: 10432_CR54 publication-title: Carcinogenesis. doi: 10.1093/carcin/bgy086 – ident: 10432_CR71 doi: 10.1007/S00428-022-03271-1 – volume: 21 start-page: 33 year: 2016 ident: 10432_CR34 publication-title: Oncol. doi: 10.1634/THEONCOLOGIST.2015-0241 – ident: 10432_CR31 doi: 10.1158/1078-0432.CCR-13-0259 – volume: 23 start-page: 739 year: 2010 ident: 10432_CR39 publication-title: Oncol Rep. doi: 10.3892/OR_00000692 – volume: 40 start-page: 317 year: 2021 ident: 10432_CR48 publication-title: J Exp Clin Cancer Res. doi: 10.1186/S13046-021-02093-4 – volume: 67 start-page: 6325 year: 2007 ident: 10432_CR68 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4261
SSID	ssj0017808
Score	2.4000368
Snippet	Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil... Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP)... Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil... Abstract Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1352
SubjectTerms	Antineoplastic Combined Chemotherapy Protocols - pharmacology Biomedical and Life Sciences Biomedicine Cancer Research Care and treatment Cell Line, Tumor Cell lines Chemoresistance Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Development and progression Diagnosis Dosage and administration Drug resistance Drug Resistance, Neoplasm - genetics Fluorouracil - pharmacology Fluorouracil - therapeutic use Health Promotion and Disease Prevention Homologous recombination deficiency Humans Male Medicine/Public Health Oncology Patient outcomes Penile cancer Penile carcinomas Penile Neoplasms - drug therapy Risk factors Surgical Oncology
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yiHgRv62uGkXwoGXbNE1eLsL6sawHF1kV9haSNF0HpDNMZ_z7fS9th-0K68Vr86Y0v7zPycsvjL0CF1QIZZVH6UwufWzQpBw1rpVF60GD0yFdNqFPTuDszHy9cNUX9YQN9MADcAdFkJgR6xbjYJCgKqegdb5oYwO1aHxKjQptpmJq3D_QUMB0RAbUQY9eGOgkskC3IyvMKWdhKLH1_-2TLwSlyw2Tl3ZNUzA6us1ujVkkPxy-_g67Fru77MaXcZ_8HnuHZk_d5rHhx6cfeU9clXzR8bDoV9T81nGssilz7DZ8FTv0DDzQ8q85_ZHf32c_jj59_3Ccjzcl5AHzmU3uMM9qnBGlj7WBKMDVvnDGGwzXThTCuwAeKifKSAR_baTCwlQuSBW89031gO11yy4-YryOit7WEg-7lKE2UoTWB6F0lNA4yFg5AWfDSCNOt1n8sqmcAGUHsC2CbRPYVmfsze43q4FE40rp97QeO0kiwE4PUC3sqBb2X2qRsee0mnY4TbozY3uoMZ-tAQN3xl4mCSLB6KjL5txt-95-_nY6E3o9CrVLnGVw46EFxIp4s2aS-zNJtNIwG34xqZWlIWpt6-Jy21uBFVviQFIZezio2W7qFT7GeZYZ0zMFnGEzH-kWPxNJuNFglMDlejupqh29U38F9o__B_ZP2E2RTE3kotpne5v1Nj5l18PvzaJfP0uG-gfAuj4O priority: 102 providerName: Directory of Open Access Journals
Title	Increased HRD score in cisplatin resistant penile cancer cells
URI	https://link.springer.com/article/10.1186/s12885-022-10432-7 https://www.ncbi.nlm.nih.gov/pubmed/36564761 https://www.proquest.com/docview/2758116566 https://pubmed.ncbi.nlm.nih.gov/PMC9789628 https://doaj.org/article/0c47687f028c4863a68fab0fed852dba
Volume	22
WOSCitedRecordID	wos000903531000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoixAX3o9AWQJC4kAjEufh8QWphVbtoavVFtBysmzHKSuh7Gqzy-9nxklWpKBKcImUeBLJk3naM58ZewPaFtYmaeQyLaPMuBJVSlPhWhJXBgRoYf1hE2I8htlMTrqmsKavdu-3JL2l9moNxfsGLSlQNzFH05GlGBfusD10d0AHNkwvvm73DgTE0LfH_PW9gQvySP1_2uPfHNLVYskrO6beEZ3c_b8p3GN3usAzPGwl5T674eoH7NZ5t7X-kH1AS0EF6q4MT6efwobgLcN5Hdp5s6R6uTrExJyCzXodLl2NxiS0JDGrkNb-m0fsy8nx54-nUXe4QmQxBFpHGkOzUkueGJdLcBx0bmItjUQPr3nMjbZgINU8cYQJWDnKRWSqbVZYY0yZPma79aJ2T1mYu4K-VhF0e5bZXGbcVsbyQrgMSg0BS3p-K9shj9MBGD-Uz0CgUC1jFDJGecYoEbB323eWLe7GtdRH9Bu3lISZ7R8sVpeqU0EV2wxzK1FhRGUzKFJdQKVNXLkScl4aHbCXJASqbUDdar46FBgC54C-PmCvPQXhZtRUmHOpN02jzi6mA6K3HVG1wFla3fU5IK8IamtAuT-gRMW2g-FXvTQqGqJquNotNo3imOR52KQiYE9a6dxOPcXHOM8kYGIgtwPeDEfq-XePKy4FyILj7zropVd1Bq25hvfP_o38ObvNvQLwiKf7bHe92rgX7Kb9uZ43qxHbETPhrzBie0fH48l05JdJ8G5ydj75NvK6_guehUfA
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagIMoL9xEo1CAkHiAicRzHeUEqR7UV7QptC-qbZTtOuxLKrta7_H5mnEOkoErwao8jeTxnPPOZkFdSW2FtmsWO6zLmxlWgUhoL19KkNrKQurDhsYliOpWnp-XXrinM99Xu_ZVksNRBraV458GSSuwmZmA6eAZx4VVyjYPHQsT82fH34e6gkIns22P-um7kggJS_5_2-DeHdLFY8sKNaXBE-7f_bwt3yK0u8KR7raTcJVdcc4_cOOqu1u-T92ApsEDdVXQy-0Q9wlvSeUPt3C-xXq6hkJhjsNms6dI1YEyoRYlZUfz37x-Qb_ufTz5O4u5xhdhCCLSONYRmlS5ZalxeSsekzk2iS1OCh9csYUZbaWSmWeoQE7B2mIuUmbZcWGNMlT0kW82icY8JzZ3Ar9UI3c65zUvObG0sE4XjstIyImnPb2U75HF8AOOHChmIFKpljALGqMAYVUTkzbBm2eJuXEr9AY9xoETM7DCwWJ2pTgVVYjnkVkUNEZXlUmRayFqbpHaVzFlldER2UQhU24A6aL7aKyAEziX4-oi8DBSIm9FgYc6Z3nivDo5nI6LXHVG9gF1a3fU5AK8QamtEuTOiBMW2o-kXvTQqnMJquMYtNl4xSPICbJKIyKNWOoetZzAM-0wjUozkdsSb8UwzPw-44mUhS8HguN720qs6g-Yv4f2TfyPfJduTk6NDdXgw_fKU3GRBGVjMsh2ytV5t3DNy3f5cz_3qedDqX54-RJQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9UwFA86Zfjit646XRTBB1fWpmmTvgjTedlQL2NT2VtI0nReGLmX217_fs9J28s6ZSC-NieFnJxPzjm_EPJGaltYm2ax47qMuXEVqJTGxrU0qY0UUgsbHpsQ06k8OyuPL03xh273oSTZzTQgSpNv9xZV3am4LPYasKoSJ4sZmBGeQYx4k9zi2EiP-frpj3UdQchEDqMyf903ckcBtf9P23zJOV1tnLxSPQ1OaXLv_49zn9ztA1K630nQA3LD-Ydk82tfcn9E3oMFwcZ1V9HDkwPaIOwlnXlqZ80C--g8hYQdg1Df0oXzYGSoRUlaUqwJNI_J98mnbx8P4_7RhdhCaNTGGkK2SpcsNS4vpWNS5ybRpSnB82uWMKOtNDLTLHWIFVg7zFHKTFteWGNMlT0hG37u3RahuSvwbzVCunNu85IzWxvLCuG4rLSMSDrwXtkekRwfxrhQITORheoYo4AxKjBGiYi8W-9ZdHgc11J_wCtdUyKWdvgwX56rXjVVYjnkXKKGSMtyWWS6kLU2Se0qmbPK6IjsoECobjB1bRHUvoDQOJcQA0TkdaBAPA2PDTvnetU06uj0ZET0tieq53BKq_v5B-AVQnCNKLdHlKDwdrT8apBMhUvYJefdfNUoBslfgFMqIvK0k9T10TP4DOdMIyJGMjzizXjFz34GvPFSyLJgcF27gySr3tA11_D-2b-R75DN44OJ-nI0_fyc3GFBF1jMsm2y0S5X7gW5bX-1s2b5Mij4b5cGTXg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+HRD+score+in+cisplatin+resistant+penile+cancer+cells&rft.jtitle=BMC+cancer&rft.au=Winkelmann%2C+Ria&rft.au=Bankov%2C+Katrin&rft.au=D%C3%B6ring%2C+Claudia&rft.au=Cinatl%2C+Jaroslav&rft.date=2022-12-23&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-022-10432-7&rft.externalDocID=10_1186_s12885_022_10432_7
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon